CSIMarket Company Name, Ticker, Suppliers, else..
 
• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Arrowhead Pharmaceuticals Inc   (NASDAQ: ARWR)
Other Ticker:  
 

Arrowhead Pharmaceuticals Inc 's Working Capital Per Sales

ARWR's Working Capital and Revenue growth

 



ARWR Working Capital Per Revenue (Mar 31 2025)
II. Quarter		 (Dec 31 2024)
I. Quarter		 (Sep 30 2024)
IV. Quarter		 (Jun 30 2024)
III. Quarter		 (Mar 31 2024)
II. Quarter
Y / Y Working Capital Change 89.86 % 172.15 % 90.61 % -10.14 % -1.21 %
Y / Y Revenue Change - -29.6 % - - -
Working Capital Per Revenue 1.08 192.31 113.87 16.96 9.68
Working Capital Per Revenue Ranking # # # # #
Seq. Working Capital Change 89.24 % -19.26 % 66.57 % -25.4 % 171.27 %
Seq. Revenue Change 21608.36 % - - - -


New: More ARWR's historic Working Capital Per Revenue Ratios >>


Financial strength information by company within the Major Pharmaceutical Preparations industry >> Back to ARWR Financial Strength Comparisons >> See ARWR Balance Sheets

Comment on ARWR's Working Capital Per Revenue in the second quarter 2025
Arrowhead Pharmaceuticals Inc 's Working Capital Per Revenue in the Q2 2025 sequentially fell to 1.08 but remained above Arrowhead Pharmaceuticals Inc 's average.

Within Healthcare sector Arrowhead Pharmaceuticals Inc has achieved the lowest Working Capital Per Revenue. While Working Capital Per Revenue remained unchanged in the Q2 2025 relative to the prior quarter at no. .
Working Capital Per Revenue Ranking
Within: No.
Industry #
Sector #
S&P 500 #


Working Capital Per Revenue Statistics
High Average Low
0
0
0
 



Financial Statements
Arrowhead Pharmaceuticals Inc 's Working Capital $ 915 Millions Visit ARWR's Balance sheet
Arrowhead Pharmaceuticals Inc 's Revenues $ 543 Millions Visit ARWR's Income Statement
Where are ARWR's Sales coming from? Visit ARWR's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Mar 31 2025, within Healthcare Sector Working Capital Per Revenue
Geron Corp  2.95 
Harvard Apparatus Regenerative Technology Inc   2.82 
Zymeworks Inc   2.79 
Madrigal Pharmaceuticals Inc   2.79 
Xoma Royalty Corporation  2.77 
Day One Biopharmaceuticals Inc   2.75 
Zomedica Corp   2.73 
Dynavax Technologies Corporation  2.71 
Utah Medical Products Inc  2.60 
Femasys Inc  2.57 
Urogen Pharma Ltd   2.55 
Protagonist Therapeutics inc   2.50 
Quanterix Corporation  2.37 
Mersana Therapeutics inc   2.36 
Nektar Therapeutics  2.34 
Ionis Pharmaceuticals Inc   2.33 
Verrica Pharmaceuticals Inc   2.32 
Keros Therapeutics Inc   2.32 
Entrada Therapeutics Inc   2.30 
Rapid Micro Biosystems Inc   2.29 
Immunocore Holdings Plc  2.27 
Gossamer Bio Inc   2.23 
Ginkgo Bioworks Holdings Inc   2.22 
Xenetic Biosciences Inc   2.22 
Humacyte Inc   2.10 
Outset Medical Inc   2.06 
Amarin Corp Plcuk  2.04 
Cvrx inc   2.04 
Moderna Inc   2.03 
Butterfly Network Inc   2.00 
Date modified: 2025-05-15T07:56:17+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com